Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business – Read more

Identify the right ovarian cancer patients for PARPi therapy in time

With MyChoice® – the most comprehensive and validated HRD test1-6

Download clinician guide

Accurate Results

Timely insights

Confident decisions

Ovarian cancer patients need the right treatment as soon as possible

HRD status provides a valuable predictive marker for PARPi effectiveness, but many patients may be missed by BRCA1 & 2 testing or assays measuring loss of heterozygosity alone.1,2,6-8

Supporting your treatment decisions in early ovarian cancer

HRD testing has life-changing consequences for every woman with ovarian cancer, and MyChoice® is here to guide treatment decisions for each one.

Accurate results

MyChoice® accurately identifies more HRD+ patients than tests that measure BRCA1 & 2 status or loss of heterozygosity alone,1,6-8 ensuring you have the most accurate information to make informed treatment decisions.

Timely insights

Local testing with MyChoice® allows easy ordering and fast results, supporting you to identify eligible patients for PARPi treatment in time.

Confident decisions

MyChoice® is a trusted partner, as the only HRD test with FDA approval,9 CE certification, recommendation in major international treatment guidelines10-12 and the most prospective phase III study data.1-5

Download clinician guide

The only HRD test validated in 3 phase III studies1-5 providing Level of Evidence 1A

Recommended by NCCN12

Somatic testing should prioritize identification of molecular alterations that inform the use of effective interventions. This includes assessing BRCA1/2, loss of heterozygosity (LOH), or homologous recombination deficiency (HRD) status in the absence of a germline BRCA mutation.

Recommended by ASCO10

Myriad MyChoice® is included in the new recommendations from The American Society of Clinical Oncology (ASCO) on the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer.

Recommended by ESMO11

Validated scar-based HRD tests can be used to guide PARP inhibitor treatment. ESMO recognizes MyChoice® is the only scar based HRD test validated in the first-line maintenance setting.

Download clinician guide

Discover more about how MyChoice® works and why it helps you identify the right ovarian cancer patients for PARPi treatment in time.

Download clinician guide

References

  1. Ray-Coquard, Isabelle, et al. “***(OLA) plus *** (BEV) as First-Line Maintenance in Ovarian Cancer.” New England Journal of Medicine, vol. 381, no. 25, 2019, pp. 2416–2428.
  2. Ray-Coquard, Isabelle, et al. “*** (OLA) plus *** (BEV) First-Line Maintenance in Ovarian Cancer: Final Overall Survival Results from the Paola-1/ENGOT-OV25 Trial.” Annals of Oncology, vol. 34, no. 8, 2023, pp. 681–692.
  3. González-Martín, Antonio, et al. “*** (NIR) in Patients with Newly Diagnosed Advanced Ovarian Cancer.” New England Journal of Medicine, vol. 381, no. 25, 2019, pp. 2391–2402.
  4. González-Martín, Antonio, et al. “Progression-Free Survival and Safety at 3.5 Years of Follow-up: Results from the Randomised Phase 3 Prima/Engot-OV26/GOG-3012 Trial of *** (NIR) Maintenance Treatment in Patients with Newly Diagnosed Ovarian Cancer.” European Journal of Cancer, vol. 189, 2023, p. 112908.
  5. Coleman, Robert L., et al. “*** (VEL) with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.” New England Journal of Medicine, vol. 381, no. 25, 2019, pp. 2403–2415.
  6. Timms, Kirsten M, et al. “Comparison of Genomic Instability Test Scores Used for Predicting PARP Activity in Ovarian Cancer.” Journal of Clinical Oncology, vol. 38, no. 15_suppl, 2020, pp. 1586–1586.
  7. Baldwin, Rae L. et al. “BRCA1 Promoter Region Hypermethylation in Ovarian Carcinoma: A Population-based Study.” Cancer Research, vol. 60, no. 19, 2000, pp. 5329-5333.
  8. Norquist, Barbara M. et al. “Inherited Mutations In Women With Ovarian Carcinoma”. JAMA Oncology, vol 2, no. 4, 2016, p. 482.
  9. Cristescu, Razvan et al. “428 Genomic Instability Metric Concordance Between Oncoscan™, Cytosnp And An Fda-Approved HRD Test”. Translational Research, 2020.
  10. Tew, William P., et al. “Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.” Journal of Clinical Oncology, vol. 40, no. 33, 2022, pp. 3878–3881.
  11. Miller, Rowan E. et al. “ESMO Recommendations On Predictive Biomarker Testing For Homologous Recombination Deficiency And PARP Inhibitor Benefit In Ovarian Cancer”. Annals Of Oncology, vol 31, no. 12, 2020, pp. 1606-1622.
  12. National Comprehensive Cancer Network. Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer. Version 1.2023.

wfwgWG

Locations

United States
Europe
Japan